Strategic partner 3SBio and Alexandria Venture Investments have both contributed to a $50m round raised by Verseau that was disclosed as it emerged from stealth.

US-based cancer immunotherapy developer Verseau Therapeutics launched with $50m in funding yesterday from investors including biotechnology producer 3SBio and life sciences real estate investment trust Alexandria Real Estate Equities. The round also featured 20/20 HealthCare Partners, Highlight Capital, Yonghua Capital, InHarv Partners and Mark Foundation for Cancer Research, while Alexandra Real Estate Equities participated through…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.